(MENAFN- IMARC Group)
The latest report by IMARC Group, titled“ Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), End User (Male, Female), and Region 2024-2032 ”, offers a comprehensive analysis of the industry, which comprises insights on the market.
What is the market size of infertility drugs?
The global infertility drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.
Factors Affecting the Growth of the Infertility Drugs Industry:
Increasing Prevalence of Infertility:
A primary factor affecting the growth of the infertility drugs industry is the rising prevalence of infertility worldwide, attributed to various reasons including delayed childbearing, lifestyle-related issues, and environmental factors. As couples increasingly seek medical assistance to conceive, the demand for infertility drugs has surged. This trend is further supported by growing awareness and social acceptance of infertility treatments, encouraging more individuals to explore medication options to enhance fertility, thereby driving the growth of the infertility drugs market.
Advancements in Medication and Treatment Protocols:
The continuous advancements in the field of reproductive medicine, including the development of more effective and safer infertility drugs, play a significant role in the industry's growth. Research and development efforts have led to the introduction of novel medications that offer higher success rates, fewer side effects, and tailored treatment options for various infertility issues. These advancements not only improve patient outcomes but also increase trust and reliance on pharmacological interventions for infertility, contributing significantly to market expansion.
Increasing Government and Insurance Support:
Financial support from governments and insurance coverage for infertility treatments, including medication, has become a critical factor in the industry's growth. In regions where healthcare policies include coverage for infertility treatments, there is a noticeable increase in the utilization of infertility drugs. Such financial support makes treatments more accessible to a broader segment of the population, reducing the economic burden on individuals seeking infertility treatments. This support is crucial in driving the demand for infertility drugs, as it lowers the barriers to accessing these often-costly treatments.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/infertility-drugs-market/requestsample
Top Companies Operating in the Infertility Drugs Industry:
Abbott Laboratories Bayer AG Ferring Pharmaceuticals Livzon Pharmaceutical Group Inc. Mankind Pharma Merck & Co. Inc. Merck KGaA Novartis AG Pfizer Inc. Sanofi S.A. Theramex
Infertility Drugs Market Report Segmentation:
By Drug Class:
Gonadotropin Aromatase Inhibitors Selective Estrogen Receptor Modulators (SERMs) Biguanides Others
Based on the drug class, the market has been segmented into gonadotropin, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others.
By Route of Administration:
Oral Intravenous Subcutaneous Intramuscular
On the basis of the route of administration, the market has been segmented into oral, intravenous, subcutaneous and intramuscular.
By Distribution Channel:
Hospital Pharmacies Retail Pharmacies Others
The market has been segmented based on the distribution channel into hospital pharmacies, retail pharmacies, and others.
By End User:
Females represent the largest segment due to the higher prevalence of infertility issues among women, combined with a wide range of pharmaceutical options available for female infertility treatments, such as ovulation induction and hormone therapies.
Regional Insights:
North America (United States, Canada) Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America (Brazil, Mexico, Others) Middle East and Africa
North America's dominance in the infertility drugs market is attributed to advanced healthcare infrastructure, high awareness and acceptance of infertility treatments, and favorable insurance coverage policies, alongside significant research and development investments in the field of reproductive medicine.
Global Infertility Drugs Market Trends:
The global infertility drugs market is witnessing several key trends, including the rising emphasis on personalized medicine, which is leading to the development of targeted treatment approaches and drugs tailored to individual patient needs and genetic profiles. There is a growing preference for non-invasive treatment options, encouraging research into oral and injectable fertility drugs with fewer side effects and higher efficacy. Additionally, the market is experiencing an increase in strategic collaborations between pharmaceutical companies and biotech firms to accelerate the development and commercialization of new infertility treatments. These trends, coupled with expanding insurance coverage for infertility treatments, are significantly shaping the market's growth trajectory, making therapies more accessible and effective.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5239&flag=C
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email:
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
MENAFN05032024004122016232ID1107936440
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.